N
News Analysis
finanznachrichten.de

www.finanznachrichten.de ·

Neutral

68409868 recursion pharmaceuticals recursion reports first quarter financial results and provides business update 399

TAX_DISEASE_LUNG_CANCERWB_1614_NUTRITIONAL_PROGRAMSWB_1609_FOOD_AND_IN_KIND_TRANSFERSWB_1615_THERAPEUTIC

All NewsRead the full story on finanznachrichten.de

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

Recursion Pharmaceuticals (RXRX) reported Q1 2026 results with clinical pipeline progress. The company has a cash runway into early 2028 with burn guidance under $390M. No direct commercial mechanism is triggered; the news is a routine quarterly update with no material price, supply, or margin impact. The sector PHARMA_BIOTECH is included due to the company's primary business, but the commercial signal is weak.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • Recursion reported Q1 2026 financial results.
  • REC-1245 showed favorable early safety and PK data.
  • First patient dosed in Phase 1 study of REC-4539 (LSD1 inhibitor).
  • Regulatory update for REC-4881 expected in H2 2026.
  • Over $500 million in milestone payments from partnered programs achieved.
68409868 recursion pharmaceuticals recursion reports first quarter financial results and provides business update 399 | finanznachrichten.de — News Analysis